Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of ceftiofur tablets in China. Welcome to wholesale bulk high quality ceftiofur tablets for sale here from our factory. Good service and reasonable price are available.
Ceftiofur Tablets, The Chinese name is Ceftiofur, and its chemical name is [6R - [6a, 7 β (Z)] -7- [(2-amino-4-thiazolyl) (methoxyimino) acetyl] amino] -3- [(2-furancarbonyl) thio] methyl] -8-oxo-5-thio-1-azabicyclo [4.2.0] oct-2-en-2-carboxylic acid. Its English aliases include Ceftiofur Free Acid, Ceftiofur Base, etc. Its chemical formula is C19H17N5O7S3, molecular weight is 523.563, and CAS accession number is 80370-57-6. It is a white to pale yellow powder that is insoluble in water, slightly soluble in acetone, and almost insoluble in ethanol.
Ceftiofur Tablets, also known as Ceftiofur, are tablets made from Ceftiofur salts or other excipients, which are convenient for patients to take orally. It may be a thin film coated tablet or a dispersed tablet, which facilitates patients to adjust the dosage according to their condition. In the market, there are various specifications of cefotaxime, such as cefotaxime sodium for injection (made into soluble salts for injection), cefotaxime with stronger stability, and cefotaxime hydrochloride (cefotaxime hydrochloride injection).
Our product
Additional information of chemical compound:
| Product Name | Ceftiofur Tablets | Ceftiofur Injection |
| Product Type | Tablets | Injection |
| Product Purity | HPLC≥99.0% | ≥99% |
| Product Specifications | Customizable | Customizable |
| Product Package | Customizable | Customizable |
|
|
|
Ceftiofur+. COA
 |
||
Certificate of Analysis |
||
|
Compound name |
Ceftiofur | |
|
CAS No. |
80370-57-6 | |
|
Grade |
Pharmaceutical grade | |
|
Quantity |
Customized | |
|
Packaging standard |
Customized | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
|
Lot No. |
20250109001 |
|
|
MFG |
Jan 12th 2025 |
|
|
EXP |
Jan 8th 2029 |
|
|
Structure |
 |
|
| TEST STANDARD | GB/T24768-2009 Industry. Stnndard | |
|
Item |
Enterprise standard |
Analysis result |
|
Appearance |
White or almost white powder |
Conformed |
|
Water content |
≤4.5% |
0.30% |
| Loss on drying |
≤1.0% |
0.15% |
|
Heavy Metals |
Pb≤0.5ppm |
N.D. |
|
As≤0.5ppm |
N.D. | |
|
Hg≤0.5ppm |
N.D. | |
|
Cd≤0.5ppm |
N.D. | |
|
Purity (HPLC) |
≥99.0% |
99.5% |
|
Single impurity |
<0.8% |
0.48% |
|
Residue on ignition |
<0.20% |
0.064% |
|
Total microbial count |
≤750cfu/g |
80 |
|
E. Coli |
≤2MPN/g |
N.D. |
|
Salmonella |
N.D. | N.D. |
|
Ethanol (by GC) |
≤5000ppm |
400ppm |
|
Storage |
Store in a sealed, dark and dry place at-20 degrees |
|
 |
||
 |
||
Clinical application and pharmacokinetics
Cefuroxime is rapidly absorbed and metabolized in animals, producing the primary metabolite Desfuroyl cefidofur (DFC) in the plasma. Its antibacterial spectrum is broad, including strong antibacterial activity against most Gram positive bacteria and some Gram negative bacteria, stable against β - lactase, and less prone to drug resistance. Its antibacterial effect is mainly exerted by inhibiting the synthesis of bacterial cell walls. When bacteria enter the animal body, they are quickly absorbed and metabolized, generating the primary metabolite Desfuroyl cefidofur (DFC) in the plasma. Due to the intact lactam ring, its antibacterial activity is basically the same as that of cefotaxime. DFC can further form inactive DFC cysteine disulfide compounds within tissues, but most of them can be excreted from urine and feces within 24 hours after intramuscular injection.
Clinical Application and Safety
Cefotaxime, as a third-generation cephalosporin antibiotic specifically designed for livestock and poultry, has a wide spectrum of antibacterial bacteria, strong antibacterial activity, long-lasting antibacterial effect, is relatively stable and not easily resistant to β - lactases, has few allergic reactions, and low residue in animal bodies. In animals, cefotaxime can exert long-lasting antibacterial effects.
Ceftiofur tablets is a third-generation cephalosporin antibiotic specifically designed for animals, widely used in veterinary clinical practice. It interacts with various drugs. The following is an introduction for you:
1. Interaction with glucocorticoid drugs
Compatibility contraindications: Cefotaxime should not be used in combination with corticosteroids such as dexamethasone.
Mechanism of action: Cefotaxime is oxidative and contains multiple amino and amide groups; Dexamethasone has reducibility and contains two vinyl bonds. Mixing the two can lead to redox or polymerization reactions. At the same time, the molecular structure of cefotaxime contains a β - lactam ring, while dexamethasone formulations contain alcohols. Mixing them will accelerate the opening of the β - lactam ring and reduce the efficacy. In addition, the anti allergic effect of dexamethasone may mask some clinical side effects of cefotaxime, delay treatment timing, and glucocorticoid drugs can inhibit the body's immune response.
2. Interaction with aminoglycoside drugs
Synergistic effect: The combination of cefotaxime and aminoglycoside drugs has a synergistic effect, which can enhance the antibacterial effect.
Caution: However, the combination of the two increases nephrotoxicity, and caution should be exercised in patients with renal dysfunction. In clinical applications, for animals with renal insufficiency, the simultaneous use of these two drugs should be avoided, or the drug dosage should be adjusted, and the renal function indicators of the animals should be closely monitored.
3. Interaction with Probenecid
Mechanism of action: Cefuroxime can delay the excretion of cephalosporins and increase the blood concentration of cefotaxime.
Clinical significance: This may increase the risk of adverse reactions to cefotaxime, such as allergic reactions, gastrointestinal reactions, etc. Therefore, when using these two drugs in combination, it is necessary to adjust the dosage of cefotaxime reasonably according to the animal's condition and physical condition, and closely observe the adverse reactions of the animal.
4. Interaction with coumarin anticoagulants
Mechanism of action: The combination of cefotaxime and coumarin anticoagulants enhances anticoagulant activity.
Clinical significance: This may lead to bleeding tendencies in animals, such as subcutaneous bleeding, nosebleeds, etc. When using the combination therapy of these two drugs, it is necessary to closely monitor the animal's coagulation indicators, such as prothrombin time (PT), activated partial thromboplastin time (APTT), etc. The dosage of anticoagulant drugs should be adjusted according to the monitoring results to avoid serious adverse reactions such as bleeding.
5. Interaction with antibacterial drugs
Mechanism of action: Cefotaxime is a reproductive fungicide, and antibacterial drugs can inhibit bacterial growth, thereby reducing the efficacy of Cefotaxime.
Clinical recommendation: In clinical treatment, the combination of cefotaxime and antibacterial drugs should be avoided to ensure the antibacterial effect of cefotaxime.
6. Interacting with Colleamine
Mechanism of action: The combination of colistin and cefotaxime in the intestine slows down the absorption of cefotaxime, reduces blood drug concentration, but does not affect the total absorption.
Response measures: If it is necessary to use these two drugs in combination, consider increasing the dosing interval to reduce the impact of interaction on the efficacy of cefotaxime.
7. Interaction with Strong Diuretics
Mechanism of action: The combination of strong diuretics and cefotaxime can exacerbate nephrotoxicity.
Caution: For animals with renal insufficiency, the simultaneous use of these two drugs should be avoided. During use, it is necessary to closely observe the renal function indicators of animals, such as blood creatinine, urea nitrogen, etc. Once abnormal renal function is found, the treatment plan should be adjusted in a timely manner.
8. Contraindications for compatibility with other drugs
Ceftiofur tablets is incompatible with drugs such as oxytetracycline hydrochloride, streptomycin hydrochloride, tetracycline hydrochloride, colistin sulfate, polymyxin E, erythromycin lactobionate, lincomycin, sulfamethoxazole, calcium chloride, etc. The combination use may lead to reduced or ineffective efficacy, and even cause various problems such as animal allergies and poisoning.
Adverse reactions and precautions
May cause allergic reactions, mainly erythema and urticaria, itching, medication fever, occasional vascular edema, asthma, and hypotension.
May cause gastrointestinal reactions such as nausea, vomiting, and diarrhea, and may also cause gastrointestinal microbiota disorders or secondary infections.
Serum alanine aminotransferase can be mildly elevated and has certain nephrotoxicity.
Local intramuscular injection can cause pain, while intravenous injection can cause phlebitis or thrombophlebitis.
There are few neurological reactions such as headaches, dizziness, and sensory disturbances.
As a third-generation cephalosporin antibiotic specifically designed for livestock and poultry, cefotaxime has a wide spectrum of antibacterial bacteria, strong antibacterial activity, long-lasting antibacterial effect, stability against β - lactase, low resistance to drug resistance, and minimal allergic reactions. Its residue in animal bodies is low. For animals, cefotaxime can exert a long-lasting antibacterial effect. When bacteria enter the animal body, they are quickly absorbed and metabolized, producing the primary metabolite difuranyl cefotaxime (DFC) in the plasma. Due to the intact lactam ring, its antibacterial activity is basically the same as cefotaxime. DFC can further form inactive DFC cysteine disulfide compounds within tissues, but most of them can be excreted from urine and feces within 24 hours after intramuscular injection.
Usage and precautions
Route of administration:
Cefotaxime is usually made into soluble salts for injection. Treat animals such as cows, pigs, and dogs. When injecting intramuscularly, the medication should be administered according to the prescribed dosage and course of treatment, and the course of treatment is generally 3-5 days.
Adverse reactions:
Cefotaxime may cause allergic reactions in clinical use, such as erythema, urticaria, itching, drug fever, etc., mainly manifested as rash, itching, nausea, drug fever, etc. It may also cause adverse reactions such as drowsiness and phototaxis. During use, it is advisable to avoid sharing with other alcohol containing drugs as much as possible to avoid masking antibacterial effects or adverse reactions.
Storage conditions:
Cefotaxime should be stored in a sealed container, avoiding high temperature, humidity, and light exposure to maintain its stability and effectiveness.
Precautions:
It is contraindicated for patients allergic to cefotaxime, used with caution in animals with renal insufficiency, and contraindicated for animals with renal insufficiency. During use, adverse reactions such as allergic reactions, drowsiness, and photophobia should be regularly monitored and strictly followed according to medical advice,
In the long history of the struggle between humans and animal diseases, the birth of cefotaxime in the late 20th century and its eventual application in tablet form marked a critical turning point. This is not only another discovery of antibiotics, but also a profound paradigm shift - it elevates veterinary medicine from simply borrowing drugs from humans to a new level of tailoring advanced therapies for animal species.
In the 1970s and 1980s, animal husbandry was rapidly developing towards intensification and scale. However, high-density farming has also led to frequent outbreaks of bacterial diseases, such as respiratory syndrome in pigs, bronchopneumonia in cows, and Escherichia coli in chickens, which have caused huge economic losses.
In 1945, Italian scientist Giuseppe Brotzu isolated this substance from cephalosporin mold in wastewater from Sardinia. Compared with the mainstream penicillin at that time, cephalosporin C exhibited a wider antibacterial spectrum and stronger stability against β - lactase (an enzyme produced by bacteria that hydrolyzes antibiotics).
In the 1970s and 1980s, research on third-generation cephalosporins reached its peak. The characteristics of this generation of drugs are strong activity against Gram negative bacteria such as Escherichia coli, Salmonella, and Pasteurella, and high stability against β - lactase. Star drugs such as cefotaxime, ceftazidime, and ceftriaxone have emerged one after another, achieving great success in human medicine.
Hot Tags: ceftiofur tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, CHLOROBENZENE-D5, 1 7 chlorodibenzo b d furan 1 yl 4 6 diphenyl 1 3 5 triazine, CAS 2189692 44 0, 2 chlorospiro benzo b fluorene 11 9 fluorene , CAS 58164 04 8, Cosmetic